LW-RT3

Description

• RT3 — Triple Receptor Agonist Research Peptide

RT3 is a next-generation research peptide engineered to simultaneously engage three metabolic receptor targets: GLP-1, GIP, and glucagon receptors. This triple agonist mechanism represents a significant advancement over single- and dual-receptor compounds in preclinical metabolic research.

• Mechanism Of Action

RT3 activates glucagon-like peptide-1 (GLP-1) receptors to potentiate glucose-dependent insulin secretion, glucose-dependent insulinotropic polypeptide (GIP) receptors to enhance incretin signaling, and glucagon receptors to promote energy expenditure and lipid oxidation. The combined activation of all three pathways creates a synergistic metabolic effect studied extensively in preclinical models of obesity and insulin resistance.